881683-80-3

Usage

Uses

Used in Pharmaceutical Synthesis:
(S)-ethyl 2-(tert-butoxycarbonylamino)-5-oxonon-8-enoate is used as a key intermediate for the synthesis of pharmaceuticals. Its ability to selectively inhibit the enzyme gamma-secretase, which is involved in the production of amyloid-beta peptides associated with Alzheimer's disease, makes it a valuable compound in the development of potential treatments for this condition.
Used in the Synthesis of Biologically Active Compounds:
(S)-ethyl 2-(tert-butoxycarbonylamino)-5-oxonon-8-enoate is also used as a building block for the synthesis of biologically active compounds, contributing to the development of new drugs and therapies.
Used in the Synthesis of Peptidomimetics:
(S)-ethyl 2-(tert-butoxycarbonylamino)-5-oxonon-8-enoate is used as a starting material for the synthesis of peptidomimetics, which are synthetic compounds that mimic the structure and function of peptides. These peptidomimetics have potential applications in various fields, including drug design and the development of novel therapeutic agents.

Upstream product

• 7103-09-5 4-but-1-enylmagnesium bromide 
• 144978-35-8 (S)-ethyl N-tert-butoxycarbonylpyroglutamate 
• 5162-44-7 1-bromo-4-butene 
• 144978-12-1 1-tert-butyl 2-ethyl (2R)-5-oxopyrrolidine-1,2-dicarboxylate 

Downstream Products

• 881683-81-4 (R)-2-tert-butoxycarbonylamino-8-nonenoic acid ethyl ester 
• 881683-81-4 ethyl (S)-((tert-butoxycarbonyl)amino)non-8-enoate 
• 769167-55-7 (S)-2-cyclopentyloxycarbonyl-amino-8-nonenoic acid 

Relevant academic research and scientific papers

CALPAIN MODULATORS AND METHODS OF PRODUCTION AND USE THEREOF

The present technology relates to compounds, kits, compositions, and methods useful for the treatment of fibrotic disease. In some aspects, the present technology provides for treatment of various diseases or disorders associated or mediated, at least in part, by calpains, such as CAPN1, CAPN2, and/or CAPN9. The present technology is generally applicable to compounds which inhibit myofibroblast differentiation.

A concise synthesis of the HCV protease inhibitor BILN 2061 and its P3 modified analogs

A concise synthesis of BILN 2061 was achieved through more efficient installation of P2 4-quinoline moiety via SN2 displacement of the β-OBs group located on the 4-hydroxyl proline intermediate, which was prepared from 4-α-hydroxyl proline analog via Mitsunobu reaction with inversion of stereochemistry. In addition, a short and practical synthesis for P3 unit is also described herein. Final assembly of four fragments for BILN 2061 was achieved with an overall yield of 58% in 4 steps from P1 to 15a. Furthermore several analogs of BILN 2061 (WX-1-WX-5) containing modifications on P3 unit were synthesized successfully using the same synthetic route as described for the parent inhibitor BILN 2061. Copyright

Design and synthesis of novel fluoro amino acids: synthons for potent macrocyclic HCV NS3 protease inhibitors

The Hepatitis C Virus (HCV) is a major health hazard and its infection is a leading cause of chronic liver disease world wide. In our efforts toward the discovery of a back up to our first clinical candidate, Boceprevir (SCH 503034), we approached the depeptidization of the molecule through macrocyclization. Herein we report the design and synthesis of fluoro amino acids with desired stereochemistry required for the synthesis of macrocyclic inhibitors with fluorine at various positions of the aliphatic chain. Biological activities of representative examples are also reported.

A NOVEL PROCESS FOR THE PREPARATION OF NONRACEMIC LONG CHAIN α-AMINO ACIDS DERIVATIVES

The present invention provides a process for the preparation of a nonracemic a-amino acid derivative from an optically active N-acyl lactam using an organometallic reagent to effect the opening of the ring followed by reduction of the ketone carbonyl to an alcohol or a methylene, or by a reductive amination to an amine, or by a ketalization reaction.